Takeda submits IBD drug candidate for FDA approval

06/25/2013 | PharmaTimes (U.K.)

Takeda Pharmaceutical has filed a biologics license application with the FDA for approval to use its experimental monoclonal antibody drug vedolizumab as a treatment for moderately to severely active Crohn's disease and ulcerative colitis. The application was based on data from four late-stage international trials involving 2,700 patients.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ